Table 5.
Resistance | Association with antibiotic use | |||
---|---|---|---|---|
No. of tests/strata | Proportion resistant (95% CI) | Odds ratio (95% CI) | p-value | |
Amoxicillin-clavulanic acid | 648 / 115 | 17 (14–21) | 1.07 (1.01–1.14) | 0.025 |
Ceftriaxone | 369 / 92 | 10 (5–18) | 1.12 (0.52–2.45) | 0.77 |
Cefepime | 369 / 92 | 3 (1–9) | 0.86 (0.59–1.25) | 0.43 |
Piperacillin-tazobactam | 369 / 92 | 21 (17–25) | 0.84 (0.61–1.18) | 0.32 |
Quinolones | 648 / 115 | 6 (3–9) | 1.37 (0.94–2.01) | 0.10 |
Trimethoprim-sulfamethoxazole | 648 / 115 | 15 (12–19) | 2.02 (1.44–2.84) | < 0.001 |
Gentamicin | 369 / 92 | 8 (4–16) | 1.82 (0.13–25.42) | 0.66 |
Combined | 3420 / 713 | 12 (8–16) | 1.06 (0.99–1.14) | 0.07 |
Results from logistic mixed effects models. The odds ratios represent the relative change in the odds for resistance for an increase in antibiotic use by 5 DDD/100 bed-days. Strata refers to year/department combinations
CI confidence interval